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Pediatric ALK-positive anaplastic large cell lymphoma (ALK+ ALCL) is usually associated
with a favorable prognosis. ALK+ ALCL associated with a leukemic phase is uncommon, but
has been associated with an aggressive clinical course and unfavorable prognosis. Overex-
pression of c-myc has been shown to be a consistent ﬁnding in ALK+, but not ALK-negative
ALCL (ALK ALCL), and the c-myc gene is considered a downstream target of deregulated
ALK signaling. We describe a pediatric ALK+ ALCL with a leukemic phase at relapse. Similar
to other rare cases described in the literature, it followed an aggressive clinical course de-
spite multiple regimens of chemotherapy and bone marrow transplantation. Lymphoma cells
showed aberrant ALK expression and c-myc overexpression. In addition to the characteristic
t(2;5)(p23;q35) translocation, a t(3;8)(q26.2;q24) translocation was also present, and c-myc
gene rearrangement was conﬁrmed by FISH analysis. The ﬁndings in this case demonstrate
the association of peripheral blood leukemic involvement and aggressive clinical course,
and suggest that other factors, such as c-myc rearrangement, may be responsible for the
aggressive clinical behavior in ALK+ ALCL. Am. J. Hematol. 82:59–64, 2007. VC 2006
Wiley-Liss, Inc.
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INTRODUCTION
Anaplastic large cell lymphomas (ALCLs) are high-
grade lymphomas characterized by a broad spec-
trum of clinical and morphologic features that com-
monly express CD30 and most often have a T-cell
phenotype. A subset of ALCL, characterized by
aberrant expression of anaplastic lymphoma kinase
(ALK), is currently recognized in the World Health
Organization classiﬁcation of hematopoietic neo-
plasms as a distinct clinicopathologic entity [1]. It is,
however, unclear whether ALK negative cases com-
prise a distinct entity. Aberrant expression of ALK,
a tyrosine kinase receptor in the insulin receptor
superfamily, is due to rearrangements of the ALK
gene on chromosome 2, most commonly as the
t(2;5)(p23;q35) reciprocal chromosomal transloca-
tion. Other variant chromosomal abnormalities are
also described with less frequency [2–5]. The t(2;5)
(p23;q35) results in a chimeric fusion protein of
nucleophosmin (NPM) and ALK with subsequent
ligand-independent activation of ALK. This translo-
cation is typically seen in children comprising 20–
50% of large cell lymphomas in this age group, and
is usually associated with a good response to ther-
apy and good survival [6,7]. Rare cases of pediatric
ALK+ ALCL with a leukemic peripheral blood in-
volvement have been described in the literature and
followed an aggressive clinical course, unlike the
typical course of ALK+ ALCL in this age group
[8–10].
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In a previous study [11], the overexpression of c-
myc was demonstrated in pediatric ALK+ but not
in ALK ALCL. The overexpression of c-myc was
considered a deﬁning characteristic of ALK+ ALCL
and deregulation of this oncogene was suggested to
play a role in ALK+ ALCL pathogenesis as a down-
stream target of ALK signaling. Although no cyto-
genetic studies documenting any aberrations involv-
ing the c-myc gene were reported in this study, chro-
mosomal structural alterations, including gains of
8q affecting the c-myc gene, were documented in an
ALCL cell line [12].
We describe a case of pediatric ALK+ ALCL,
which followed an unusually aggressive clinical course
terminating in a leukemic phase. Despite multiple
intensive chemotherapy regimens and bone marrow
transplantation, the patient died of widely dissemi-
nated disease. In addition to the characteristic t(2;5)
(p23;q35) translocation, a t(3;8)(q26.2;q24) transloca-
tion was also detected and rearrangement of the c-
myc gene was conﬁrmed by FISH analysis. Expression
of the c-myc protein was demonstrated by immuno-
histochemical (IHC) staining. This case suggests an
association between leukemic involvement and aggres-
sive clinical course in ALK+ ALCL. In addition, this
is the ﬁrst reported case of ALK+ ALCL with a bal-
anced reciprocal translocation t(3;8)(q26;q24) resulting
in c-myc rearrangement, as a mechanism for c-myc
expression in ALK+ ALCL and possibly poor prog-
nostic indicator.
MATERIALS AND METHODS
Morphological assessment was performed on
Wright-Giemsa-stained smears and cytospins from
peripheral blood and pleural ﬂuids, and standard
H&E-stained sections from formalin-ﬁxed, parafﬁn-
embedded tissue. Immunophenotyping was performed
using combined IHC and ﬂow cytometric analysis.
Flow cytometry was performed on peripheral blood
and pleural ﬂuid specimens using directly conjugated
antibodies (Becton Dickinson, San Diego, CA) and
analyzed on a 4-color FACSCalibur ﬂow cytometer
(Becton Dickinson) using the CellQuest software
(Becton Dickinson). IHC analysis was performed on
formalin-ﬁxed, parafﬁn-embedded sections using the
Dako Envision plus system for detection (DAKO,
Carpinteria, CA) and commercially available anti-
bodies. Cytogenetic analysis was performed by con-
ventional G-banded chromosome analysis and ﬂuo-
rescence in situ hybridization (FISH) using the LSI
c-myc probe (VYSIS, Downer’s Grove, IL) hybri-
dized using standard methods. Hybridization signals
were scored on Nikon Eclipse 600 microscope at-
tached to CytoVision imaging system (Applied
Imaging, Santa Clara, CA). SKY was performed on
metaphase preparations using human SKYPaint kit
obtained from Applied Spectral Imaging (Carlsbad,
CA) according to the manufacturer’s protocol. SKY
images were acquired with SD200 Spectra cube
mounted on Nikon Eclipse 800 microscope by using
SKY optical ﬁlter (Chroma Technology, Brattle-
boro, VT) analyzed using the SKY View software.
Molecular analysis of the T-cell receptor gamma
(TCR g) gene was performed using polymerase chain
reaction (PCR)-heteroduplex analysis with poly-
acrylamide gel electrophoresis (PAGE) and V1, V9,
V10/11, J1/2, JP, and JP1/P2 primers. EBV infection
status was investigated by in situ hybridization
(ISH) for EBV-encoded RNAs (EBER 1-2, Ventana
INFORM EBER, Tucson, AZ).
CASE REPORT
A 13-year-old boy presented with a 3-week his-
tory of left lower quadrant pain and left inguinal
lymphadenopathy. Since the lymphadenopathy failed
to respond to antibiotics, a lymph node biopsy was
performed and diagnosed as small cell variant of
ALK+ ALCL. Initial peripheral blood and bone
marrow examinations were negative for malignant
cells. The patient was initially treated with an induc-
tion regimen with Vincristine (1.5 mg/m2 on days 1,
8, 15, 22, 29), Doxorubicin (75 mg/m2 on day 1 and
22) and Prednisone (40 mg/m2 days 1–28). There
was an initial clinical response with reduction of
lymphadenopathy, but mild lymphadenopathy per-
Fig. 1. (a) Peripheral blood smear with abundant neoplas-
tic cells, some showing highly irregular, convoluted nuclei
(Wright-Giemsa, 1000X). (b) Lymph node biopsy with a
rare hallmark cell (arrow) and medium-sized neoplastic
cells in prominent sinusoidal and para-cortical distribution
(H&E stain, 400X). [Color ﬁgure can be viewed in the
online issue, which is available at www.interscience.wiley.
com.]
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sisted and worsened with recovery of peripheral blood
counts.
During the second round of chemotherapy, the
patient developed pleural effusions with respiratory
distress. A chest CT scan showed bilateral pleural
effusions with hilar and mediastinal lymphadenopa-
thy. Pleural ﬂuid and CSF samples were taken, and
both were positive for malignant lymphoma cells,
conﬁrmed by cytogenetics. Re-induction chemother-
apy with COPADM1 as per the CCG 5961 protocol
was initiated, followed by autologous stem cell
harvest and rescue, leading to stabilization of his
Fig. 2. Spectral karyotype (SKY) shows t(2;5) and t(3;8) translocations (arrows). [Color ﬁgure can be viewed in the
online issue, which is available at www.interscience.wiley.com.]
Fig. 3. FISH using the c-myc break apart probe shows rearrangement of c-myc (arrows). [Color ﬁgure can be viewed in
the online issue, which is available at www.interscience.wiley.com.]
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clinical condition. A reduced intensity allogeneic
stem cell transplant from an HLA-matched sibling
was performed. Shortly after transplantation, his
clinical condition deteriorated with a rapid re-accu-
mulation of the pleural effusions and the develop-
ment of a signiﬁcant leukocytosis, WBC 39.5 with
>50% neoplastic cells (Fig. 1a). Examination of pe-
ripheral blood and bone marrow by morphology,
ﬂow cytometric analysis, and cytogenetics conﬁrmed
relapsed ALCL. The patient’s clinical status contin-
ued to deteriorate rapidly and he died of disease
soon thereafter (less than 6 months from initial pre-
sentation).
RESULTS
Morphologic assessment of H&E-stained sections
of the lymph node showed predominantly small to
medium-sized lymphoid cells with only rare large
\anaplastic" cells in a prominent sinusoidal and
para-cortical distribution (Fig. 1b). Wright-Giemsa-
stained smears and cytospins of the peripheral blood
and pleural ﬂuid, respectively, showed numerous small
to medium-sized neoplastic lymphoid cells with
irregular, convoluted nuclei accounting for >50% of
WBC in the peripheral blood. IHC analysis per-
formed on formalin-ﬁxed, parafﬁn-embedded sec-
tions of the lymph node biopsy showed neoplastic
cells with the following phenotype: CD45+,
CD30+, EMA+, TIA-1+, CD56+, CD43+, ALK+,
and c-myc+. There was no detectable expression of
CD15, CD2, CD3, CD5, CD4, CD8, CD20, CD22,
CD79a, bcl-6, and Pax5. In situ hybridization for
EBER was negative in neoplastic cells. Flow cyto-
metric analysis of the peripheral blood and pleural
ﬂuid specimens detected a neoplastic population of
cells with an identical phenotype. These histologic
and immunophenotypic features are diagnostic of
the small cell variant of ALK+ ALCL. Conven-
tional G-banded karyotyping and spectral karyotyp-
ing (SKY) showed a diploid chromosome comple-
ment (46 XY) with two clonal translocations: t(2;5)
(p23;q35) and t(3;8)(q26.2;q24) (Fig.2). FISH analy-
sis conﬁrmed rearrangement of ALK to NPM and
rearrangement of c-myc (Fig.3) to an unknown gene
partner. Molecular analysis for TCR g gene rear-
rangement by PCR-heteroduplex was repeatedly
polyclonal.
DISCUSSION
Leukemic peripheral blood involvement is a well-
known occurrence in a variety of non-Hodgkin B
and T cell lymphomas, especially small lymphocytic
lymphoma/chronic lymphocytic leukemia, splenic
marginal zone lymphoma, mantle cell lymphoma,
adult T-cell leukemia lymphoma, and mycosis fun-
goides (Sezary syndrome). Presentation of ALCL in
a leukemic phase, either at presentation or at relapse,
has rarely been reported, mostly as case reports
[9,10]. Two small series of four and three pediatric
patients with ALK+ ALCL with a leukemic phase
were reported by Bayle et al. [13] and Onciu et al.
[8], respectively. In the most recent series [8], a re-
view of the literature showed only 12 total reported
cases, nine of which were pediatric patients. The
majority (75%) of patients had respiratory distress,
pleural effusions, or diffuse interstitial lung inﬁl-
trates. In 11 of the 12 patients, there was widespread
disease with involvement of extranodal sites. Periph-
eral blood involvement was usually prominent (WBC
range 15–151,000 with 5–92% lymphoma cells) with
rare and usually minimal involvement of the bone
marrow. The most common histologic type reported
was the small cell variant (9 of 12), which was previ-
ously associated with frequent bone marrow involve-
ment and a worse prognosis [14]. CD30 expression
was demonstrated in all cases but the frequency of
detecting a T-cell phenotype, either by immunophe-
notyping or PCR analysis, was variable. In addition,
the expression of myeloid associated antigens, CD13
and CD11b, was commonly observed. The classical
t(2;5) translocation was documented in most cases,
and one case showed a variant t(2,19) translocation.
Overall, these cases consistently had a poor progno-
sis with poor response to therapy and frequent
relapses resulting in death from disease.
In our case, leukemic peripheral blood involve-
ment was a late feature, observed during relapse
and disease progression. Although the characteristic
t(2;5) translocation was present in our case, the neo-
plastic cells also had an unusual translocation involv-
ing the c-myc gene on chromosome 8. In a previous
study of ALCLs, approximately 30% were shown to
contain abnormalities of the c-myc gene product
[15]. However, the ALCLs studied contained both
ALK and ALK+ ALCLs. Chromosomal struc-
tural alteration of the c-myc gene containing 8q
region have also been identiﬁed in an ALK+ ALCL
cell line [12]. The expression of c-myc RNA is
increased with ALK activation, and c-myc protein
overexpression is consistently present in pediatric
ALK+ ALCLs [11]. These observations suggest
that c-myc may be a downstream effector of the
ALK signaling cascade and may play a role in lym-
phomagenesis. However, the mechanism of c-myc
overexpression is still unclear. In our case, a recipro-
cal translocation involving the c-myc gene and an
unknown gene on chromosome 3q26.2 could repre-
sent one possible mechanism.
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A similar t(3;8)(q26;q24) translocation was recently
reported in a small series of patients with myelo-
dysplastic syndromes (MDS) and/or acute myeloid
leukemias (AML) [16]. However, the genes involved
are unknown. The 3q26 region contains a candidate
gene, the EVI1 (ecotropic virus integration site 1)
protooncogene, that has been reported to be involv-
ed in translocations with multiple partners in cases
of AML [17]. However, involvement of c-myc has
not been reported. Thus, the t(3;8) translocation
seen in our case probably involve different loci.
Another candidate on chromosome 3 is the human
transferrin receptor gene, previously localized to the
3q26.2 region, and associated with various nonlym-
phoid and lymphoid neoplasms [18,19].
One of the interesting immunophenotypic features
of this case is CD56 expression. Although CD56
expression in ALCL has been previously described,
the association of CD56 expression with c-myc and
ALK is unclear. In a large study comprising of 143
cases of both ALK+ and ALK ALCL, CD56
expression was found in 18% of the cases and asso-
ciated with a higher incidence of bone marrow
involvement and a poor prognosis [20]. In another
study of both ALK+ and ALK ALCLs, CD56
expression was seen in 36% of ALCLs and TIA-1
expression in 60% of ALCLs [21]. In our case, both
CD56 expression and a leukemic peripheral blood
involvement were associated with an aggressive clini-
cal course [8,20]. Although previous studies have sug-
gested that alternative ALK abnormalities behave
similar to cases with the classic NPM-ALK translo-
cations [7], the behavior of cases with additional
cytogenetic abnormalities involving other genes, in
our case c-myc, is unclear.
Immunophenotypic analysis of ALCL using B-
and T-cell antigens has revealed three subsets: T-,
null-, and B-cell with the vast majority being of the
T- and null-cell types [22,23]. Although many null-
cell type ALCLs have shown clonal rearrangement
of TCR genes and expression of cytotoxic molecules
including TIA-1 [21,24], a minor (10%) subset lack
TCR gene rearrangements [24]. In addition, cyto-
toxic granules including TIA-1 are also expressed by
natural-killer cells. The presence of this null-cell
ALCL subset with expression of myeloid antigens,
CD56, and cytotoxic molecules has led some
authors to propose a myeloid-NK-cell origin for a
minor subset of ALCLs [25]. However, CD13,
CD56, and TIA-1 expression have all been reported
in ALCLs of T-cell phenotype [20,24,26]. In addi-
tion, ALCLs are generally not associated with EBV,
except in occasional cases after solid organ trans-
plantation [27,28]. Our present case shares many
similarities with this myeloid-NK-cell-like subset
showing a null-cell phenotype, expression of CD13,
CD56, and TIA-1. In addition, molecular analyses
for TCR g gene rearrangement by PCR-heterodu-
plex were repeatedly polyclonal.
In conclusion, we present a case of ALK+ ALCL
with an unusual phenotype, an unusually aggressive
clinical course with a leukemic involvement of the
peripheral blood, and an complex genotype includ-
ing both NPM-ALK and t(3;8)(q26.2;q24) trans-
locations. This case reinforces the poor prognosis
associated ALK+ ALCLs with a peripheral blood
involvement. In addition, the presence of aberrant
antigen expression can be a diagnostic challenge if
comprehensive immunophenotyping is lacking. Finally,
it suggests that the presence of c-myc abnormalities in
addition to ALK activation may be associated with an
unusually aggressive disease course.
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